Physician profile
Christopher Canfield
NPI 1457855652
$3,405.25
in general payments reported to CMS, 2019-2025
23 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.76 · 2022: $128 · 2023: $813 · 2024: $1,002 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $392.37 | 2019-2024 | Lokelma |
| Glaxosmithkline, LLC. | $365.63 | 2023-2025 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $298.28 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $295.17 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $259.21 | 2024-2025 | |
| Ardelyx, INC. | $230.21 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Novo Nordisk INC | $225.72 | 2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $221.59 | 2023-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $195.73 | 2024-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $144.64 | 2023-2025 | |
| Amgen INC. | $135.73 | 2024-2025 | Tavneos |
| Akebia Therapeutics INC | $125.37 | 2024-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $124.25 | 2024-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $74.25 | 2023-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.27 | 2023-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $60.58 | 2024-2025 | Acthar |
| Nxstage Medical, INC. | $45.19 | 2022-2025 | Nxstage System One |
| Vifor Pharma, INC. | $35.93 | 2024-2025 | Veltassa |
| Kyowa Kirin, INC. | $27.76 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.00 | 2025 | Livtencity |
| Opko Pharmaceuticals, LLC | $20.52 | 2024 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $20.46 | 2025 | Empaveli |
| Abbott Laboratories | $16.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Canfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.